Leukemia News
Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia Patients May Benefit from Sprycel/Chemotherapy Combination (July 28, 2010)The initial report of a Phase II study evaluating Sprycel® (dasatinib) combined with chemotherapy for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) indicates that 94% of patients achieve a complete remission.... Continue Reading
Cell Phone Towers and Childhood Cancer Risk (July 1, 2010)Recent findings indicate that children who are exposed to radiofrequency fields from cell phone towers before birth do not have an increased risk of early childhood cancer. This study was published in the British Medical Journal. The health effects—notably,... Continue Reading
Mylotarg Withdrawn from Market in United States (June 23, 2010)Mylotarg® (gemtuzumab ozogamicin), a drug used for the treatment of acute myeloid leukemia (AML), will be withdrawn from the U.S. market following a recent clinical trial that raised new concerns about safety and failed to demonstrate clinical benefit. Mylotarg... Continue Reading
Tasigna Approved for Initial Treatment of Chronic Myeloid Leukemia (June 22, 2010)The U.S. Food and Drug Administration has expanded the approval of Tasigna® (nilotinib) to include the initial treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. Each year in the United States, approximately... Continue Reading
Sprycel May Be More Effective than Gleevec for Initial Treatment of CML (June 7, 2010)In the initial treatment of chronic myeloid leukemia (CML), Sprycel® (dasatinib) produces higher response rates than Gleevec® (imatinib). These results were presented at the 2010 annual meeting of the American Society of Clinical Oncology. Each year... Continue Reading
Study Evaluates Anthracycline-related Heart Problems in Childhood Cancer Survivors (May 28, 2010)Children with particular variants of drug-metabolizing genes may be more likely than other children to develop heart problems after low doses of anthracycline chemotherapy. The results of this study will be presented at the 2010 annual meeting of the... Continue Reading
Study Evaluates Long-term Efficacy of Peripheral Blood Stem Cell Transplant Versus Bone Marrow Transplant (April 30, 2010)For leukemia patients who undergo allogeneic stem cell transplantation, 10-year results indicate that bone-marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) produce similar rates of overall and leukemia-free survival.... Continue Reading
Rituxan Approved for Chronic Lymphocytic Leukemia (February 24, 2010)The U.S. Food and Drug Administration (FDA) has expanded the approval of Rituxan® (rituximab) to include the treatment of certain patients with chronic lymphocytic leukemia. Chronic lymphocytic leukemia (CLL) is the most common adult leukemia with... Continue Reading
Tasigna May Be More Effective than Gleevec for Initial Treatment of CML (January 28, 2010)In the initial treatment of chronic myeloid leukemia (CML), Tasigna® (nilotinib) appears to produce higher response rates than Gleevec® (imatinib) 400 mg/day. These results were presented at the 2009 meeting of the American Society of Hematology... Continue Reading
Arzerra™ Approved for Refractory Chronic Lymphocytic Leukemia (October 28, 2009)The targeted therapy Arzerra™ (ofatumumab) has been granted accelerated approval by the U.S. Food and Drug Administration for treatment of patients with chronic lymphocytic leukemia (CLL) that is refractory to Fludara® (fludarabine) and Campath® (alemtuzumab). Chronic... Continue Reading
Latest Leukemia News By Stage
Acute Lymphoblastic Leukemia
Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia Patients May Benefit from Sprycel/Chemotherapy Combination (July 28, 2010)
The initial report of a Phase II study evaluating Sprycel® (dasatinib) combined with chemotherapy for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) indicates that 94% of patients achieve a complete remission.... Continue Reading
Study Evaluates Anthracycline-related Heart Problems in Childhood Cancer Survivors (May 28, 2010)Children with particular variants of drug-metabolizing genes may be more likely than other children to develop heart problems after low doses of anthracycline chemotherapy. The results of this study will be presented at the 2010 annual meeting of the... Continue Reading
Study Evaluates Long-term Efficacy of Peripheral Blood Stem Cell Transplant Versus Bone Marrow Transplant (April 30, 2010)For leukemia patients who undergo allogeneic stem cell transplantation, 10-year results indicate that bone-marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) produce similar rates of overall and leukemia-free survival.... Continue Reading
Eliminating Preventive Radiation May Benefit Children with ALL (June 26, 2009)Eliminating Preventive Radiation May Benefit Children with ALL Children with acute lymphoblastic leukemia (ALL) who are treated with effective, risk-adjusted chemotherapy regimens have good outcomes and may safely be able to avoid preventive radiation... Continue Reading
Developments in the Treatment of Acute Lymphoblastic Leukemia: Update from ASH 2008 (March 8, 2009)Developments in the Treatment of Acute Lymphoblastic Leukemia: Update from ASH 2008 Several studies presented at the 2008 American Society of Hematology (ASH) meeting focused on improving the outcome of acute lymphoblastic leukemia (ALL) in children and... Continue Reading
More Acute Lymphoblastic LeukemiaAcute Myeloid Leukemia
Mylotarg Withdrawn from Market in United States (June 23, 2010)
Mylotarg® (gemtuzumab ozogamicin), a drug used for the treatment of acute myeloid leukemia (AML), will be withdrawn from the U.S. market following a recent clinical trial that raised new concerns about safety and failed to demonstrate clinical benefit. Mylotarg... Continue Reading
Study Evaluates Long-term Efficacy of Peripheral Blood Stem Cell Transplant Versus Bone Marrow Transplant (April 30, 2010)For leukemia patients who undergo allogeneic stem cell transplantation, 10-year results indicate that bone-marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) produce similar rates of overall and leukemia-free survival.... Continue Reading
Stem Cell Transplants Effective for Breast Cancer Survivors with Secondary Leukemia (July 20, 2009)Stem cell transplantation is an effective treatment option for breast cancer survivors who develop acute leukemia or myelodysplasia following adjuvant chemotherapy, according to the results of a study published in the Annals of Oncology.[1] Breast cancer... Continue Reading
Allogeneic Stem Cell Transplantation Improves Survival for Intermediate and Poor-risk AML (July 10, 2009)Allogeneic stem cell transplantation during first complete remission improves relapse-free and overall survival in patients with intermediate and poor-risk acute myeloid leukemia (AML), according to the results of a study published in the Journal of the... Continue Reading
Compressed Dose-dense Induction with S-HAM Effective and Less Toxic for AML Patients (May 5, 2009)The dose-dense induction regimen S-HAM (sequential high-dose cytarabine [Cytosar®] and mitoxantrone [Novantrone®] followed by Neulasta® [pegfilgrastim]) delivered in two induction cycles over 11-12 days instead of 25-29 days is highly effective... Continue Reading
More Acute Myeloid LeukemiaAcute Promyelocytic Leukemia
Sorry, there are no articles available for this cancer stage.
More Acute Promyelocytic LeukemiaAdult Acute Lymphoblastic Leukemia
Sorry, there are no articles available for this cancer stage.
More Adult Acute Lymphoblastic LeukemiaChildhood Acute Lymphoblastic Leukemia
Sorry, there are no articles available for this cancer stage.
More Childhood Acute Lymphoblastic LeukemiaChronic Lymphoblastic Leukemia
Arzerra™ Approved for Refractory Chronic Lymphocytic Leukemia (October 28, 2009)
The targeted therapy Arzerra™ (ofatumumab) has been granted accelerated approval by the U.S. Food and Drug Administration for treatment of patients with chronic lymphocytic leukemia (CLL) that is refractory to Fludara® (fludarabine) and Campath® (alemtuzumab). Chronic... Continue Reading
FCR-Lite Is Safe and Effective in Previously Untreated CLL (March 8, 2009)FCR-Lite Is Safe and Effective in Previously Untreated CLL FCR-Lite, a drug regimen that consists of Fludara® (fludarabine), Cytoxan® (cyclophosphamide), and Rituxan® (rituximab), is highly effective in previously untreated patients with chronic lymphocytic... Continue Reading
Sequential Treatment with Fludara®, Cytoxan®, and Rituxan® Produces High-quality Responses in CLL (March 8, 2009)Sequential Treatment with Fludara®, Cytoxan®, and Rituxan® Produces High-quality Responses in CLL Patients with chronic lymphocytic leukemia (CLL) treated with Fludara® (fludarabine), followed by consolidation with Cytoxan® (cyclophosphamide), and... Continue Reading
Revlimid® Shows Promise as First-line Therapy of CLL (March 8, 2009)Revlimid® Shows Promise as First-line Therapy of CLL According to the results of two studies presented at the 2008 annual meeting of the American Society of Hematology (ASH), Revlimid® (lenalidomide) appears to be effective for the initial treatment... Continue Reading
Arzerra™ Effective For CLL (March 8, 2009)Arzerra™ Effective For CLL Arzerra™ (ofatumumab), a human anti-CD20 monoclonal antibody, is effective for the treatment of patients with refractory chronic lymphocytic leukemia (CLL), according to the results of a study presented at the annual meeting... Continue Reading
More Chronic Lymphoblastic LeukemiaChronic Lymphocytic Leukemia
Rituxan Approved for Chronic Lymphocytic Leukemia (February 24, 2010)
The U.S. Food and Drug Administration (FDA) has expanded the approval of Rituxan® (rituximab) to include the treatment of certain patients with chronic lymphocytic leukemia. Chronic lymphocytic leukemia (CLL) is the most common adult leukemia with... Continue Reading
Arzerra™ Approved for Refractory Chronic Lymphocytic Leukemia (October 28, 2009)The targeted therapy Arzerra™ (ofatumumab) has been granted accelerated approval by the U.S. Food and Drug Administration for treatment of patients with chronic lymphocytic leukemia (CLL) that is refractory to Fludara® (fludarabine) and Campath® (alemtuzumab). Chronic... Continue Reading
Abnormal Cells Identified in Blood Years Before Diagnosis of CLL (March 9, 2009)According to the results of a study published in the New England Journal of Medicine, chronic lymphocytic leukemia (CLL) appears to be preceded by a condition known as monoclonal B-cell lymphocytosis (MBL). Chronic lymphocytic leukemia is the most common... Continue Reading
More Chronic Lymphocytic LeukemiaChronic Myeloid Leukemia
Tasigna Approved for Initial Treatment of Chronic Myeloid Leukemia (June 22, 2010)
The U.S. Food and Drug Administration has expanded the approval of Tasigna® (nilotinib) to include the initial treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. Each year in the United States, approximately... Continue Reading
Sprycel May Be More Effective than Gleevec for Initial Treatment of CML (June 7, 2010)In the initial treatment of chronic myeloid leukemia (CML), Sprycel® (dasatinib) produces higher response rates than Gleevec® (imatinib). These results were presented at the 2010 annual meeting of the American Society of Clinical Oncology. Each year... Continue Reading
Study Evaluates Long-term Efficacy of Peripheral Blood Stem Cell Transplant Versus Bone Marrow Transplant (April 30, 2010)For leukemia patients who undergo allogeneic stem cell transplantation, 10-year results indicate that bone-marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) produce similar rates of overall and leukemia-free survival.... Continue Reading
Tasigna May Be More Effective than Gleevec for Initial Treatment of CML (January 28, 2010)In the initial treatment of chronic myeloid leukemia (CML), Tasigna® (nilotinib) appears to produce higher response rates than Gleevec® (imatinib) 400 mg/day. These results were presented at the 2009 meeting of the American Society of Hematology... Continue Reading
Sprycel® Superior to High-dose Gleevec® in Gleevec-resistant CML (July 1, 2009)Sprycel® (dasatinib) produces a higher response rate and improves progression-free survival in patients with chronic myeloid leukemia (CML) who have grown resistant to Gleevec® (imatinib), according to the results of a study published early online in... Continue Reading
More Chronic Myeloid LeukemiaHairy Cell Leukemia
Sorry, there are no articles available for this cancer stage.
More Hairy Cell LeukemiaScreening/Prevention Leukemia
Cell Phone Towers and Childhood Cancer Risk (July 1, 2010)
Recent findings indicate that children who are exposed to radiofrequency fields from cell phone towers before birth do not have an increased risk of early childhood cancer. This study was published in the British Medical Journal. The health effects—notably,... Continue Reading
Formaldehyde Exposure May Increase Risk of Blood and Lymphatic Cancers (June 23, 2009)Formaldehyde Exposure May Increase Risk of Blood and Lymphatic Cancers Industrial workers who are exposed to formaldehyde may be at an increased risk of dying from blood and lymphatic cancers, particularly myeloid leukemia but also Hodgkin’s lymphoma... Continue Reading
Cyclophosphamide May Increase Cancer Risk Among Patients with Rheumatoid Arthritis (March 8, 2009)Cyclophosphamide May Increase Cancer Risk Among Patients with Rheumatoid Arthritis A large study conducted in Canada reveals that patients who are treated for rheumatoid arthritis (RA) with the drug cyclophosphamide may have an increased risk for developing... Continue Reading
Being Overweight Associated with Increased Risk of Several Cancers (March 8, 2009)Being Overweight Associated with Increased Risk of Several Cancers Excess bodyweight increases the risk of developing several types of cancer, according to results recently published in The Lancet. It is estimated that in the United States, one out of... Continue Reading
More Screening/Prevention Leukemia